Top Markets
Coin of the day
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
Ранг среди акций #13175
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Цена акции
$8.46
Последняя синхронизация: 2026-08-28
Рыночная капитализация
$514.33M
Изменение (1 день)
-2.08%
Изменение (1 год)
128.03%
Страна
US
Торговля Kyverna Therapeutics, Inc. (KYTX)

Категория

История цены акций Kyverna Therapeutics, Inc. (KYTX)
Наивысшая цена закрытия: $8.33 2026-08-01

Наименьшая цена закрытия: $28.70 2024-02-01
История цены акций Kyverna Therapeutics, Inc. с 2024 по 2026
Годовая динамика цены акций
Год Результативность
2026 (TTM) -5.16%
2025 89.56%
2024 0.00%
Цена акций похожих компаний или конкурентов
Компания Цена акций Изменение 1г% Страна
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.01 -13.08%
AU
$138.18 473.58%
US
$752.76 6.28%
CH